DUBLIN, Ireland, Oct. 6, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, is pleased to announce that it will host an Animal Health Symposium from 10:30AM to 12:30PM ET on Monday, November 23rd, 2015 at Le Parker Meridien Hotel in New York City.
An expert forum, intended to provide investors and analysts with an educational experience on unmet needs in the companion animal health sector, will be the focal point of this event. In addition, Nexvet will provide an update on the Company's programs in pain, inflammation and immuno-oncology, and how these programs aim to address major unmet medical needs in both dogs and cats.
"The U.S. companion animal market has grown consistently at six percent per year over the last decade, and has proven resilient to economic volatility. It is a market with significant opportunity for investment, and companies such as Nexvet that are focused on providing innovative solutions are key to its future. This symposium will facilitate discussion between the investment and veterinarian communities and explore how innovation could deliver new products where unmet medical needs still exist," explained Dr. Mark Heffernan, Chief Executive Officer of Nexvet.
To register for this event, please send an email request to IR@nexvet.com with your name, company and phone number. Le Parker Meridien Hotel is located at 119 West 56th Street, New York, N.Y. 10019-3318. A detailed agenda will be distributed one week prior to the symposium.
About Nexvet (www.nexvet.com)
Nexvet is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet's proprietary PETization™ platform is designed to rapidly create monoclonal antibodies ("mAbs") that are recognized as "self" or "native" by an animal's immune system, a property Nexvet refers to as "100% species-specificity." Nexvet's product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, through conducting drug discovery in Australia, clinical development in the United States and biomanufacturing in Ireland.
CONTACT: Further information: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 4 email@example.com Media David Salisbury Berry & Company Public Relations +1 212-253-8881 firstname.lastname@example.org
Source:Nexvet Biopharma plc